Literature DB >> 18765293

Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.

Mirjam T Epping1, René Bernards.   

Abstract

Histone deacetylase inhibitors comprise a variety of natural and synthetic compounds, which have in common that they inhibit enzymes that mediate the removal of acetyl groups from a range of proteins, including nucleosomal histones. Histone deacetylase inhibitors have anti-cancer activities in vitro and in vivo and are used in the clinic for the treatment of advanced cutaneous T cell lymphoma. The molecular pathways targeted by these compounds are discussed with an emphasis on the effects of these compounds on retinoic acid signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765293     DOI: 10.1016/j.biocel.2008.07.020

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  6 in total

1.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

Review 2.  γ-H2AX and other histone post-translational modifications in the clinic.

Authors:  Christophe E Redon; Urbain Weyemi; Palak R Parekh; Dejun Huang; Allison S Burrell; William M Bonner
Journal:  Biochim Biophys Acta       Date:  2012-03-09

3.  Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.

Authors:  Bevin Zimmerman; Aaron Sargeant; Kristina Landes; Soledad A Fernandez; Ching-Shih Chen; Michael D Lairmore
Journal:  Leuk Res       Date:  2011-07-29       Impact factor: 3.156

4.  HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.

Authors:  Christopher S Ward; Pia Eriksson; Jose L Izquierdo-Garcia; Alissa H Brandes; Sabrina M Ronen
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 5.  HDAC inhibitors in kidney development and disease.

Authors:  Lauren L Brilli; Lisa M Swanhart; Mark P de Caestecker; Neil A Hukriede
Journal:  Pediatr Nephrol       Date:  2012-10-07       Impact factor: 3.714

6.  Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation.

Authors:  Mu He; Zhixin Qiao; Yanbing Wang; Qiyuan Kuai; Changlan Li; Yu Wang; Xingwei Jiang; Xuanlin Wang; Weijing Li; Min He; Suping Ren; Qun Yu
Journal:  PLoS One       Date:  2016-11-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.